TP53 and mantle cell lymphoma: In addition, we see multiple features associated with an adverse clinical course in this case, including diffuse P53 expression by IHC, TP53 mutation, high Ki67 proliferation index, and transformed blastoid MCL (compared to de novo) (11–13).